Trial Profile
A Multicenter, Open-Label Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of Nonacog-Alfa (BeneFIX) In Subjects With Moderately Severe To Severe Hemophilia B (FIX:C'/=2%)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Nonacog alfa (Primary)
- Indications Haemophilia B; Haemorrhage
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 08 Mar 2016 Results published in Pfizer media release.
- 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2014 New trial record